Tier 2 — strong

The Influence of Single-Dose and Short-Term Administration of Quercetin on the Pharmacokinetics of Midazolam in Humans

Mai Anh Nguyen, Petra Staubach, Siegfried Wolffram, Peter Langguth
Journal of pharmaceutical sciences 2015 104(9):3199

Bibliography

PubMed
PMID 25988261
DOI
10.1002/jps.24500
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignHuman crossover pharmacokinetic interaction study
ModelHuman intervention research
Sample10 healthy volunteers; 3 also received intravenous midazolam
InterventionQuercetin 1,500 mg once and then daily for one week; oral midazolam 7.5 mg
DurationSingle dose and 1 week
EndpointsExposure and pharmacokinetics

What the study showed, in plain terms

Published in 2015, this source examined safety, interactions and special populations. Design: Human crossover pharmacokinetic interaction study. Sample/model: 10 healthy volunteers; 3 also received intravenous midazolam. The exposure or intervention was Quercetin 1,500 mg once and then daily for one week; oral midazolam 7.5 mg. Follow-up or treatment period: Single dose and 1 week.

A single dose did not alter midazolam pharmacokinetics. Repeated quercetin showed a nonsignificant trend toward lower oral midazolam exposure; intravenous results differed.

Very small study with route-dependent findings; the oral exposure ratio confidence interval crossed no effect. It does not support a universal CYP3A inhibition claim.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Interactions: Medicines, Evidence and Precautions. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • A single dose did not alter midazolam pharmacokinetics.
  • Repeated quercetin showed a nonsignificant trend toward lower oral midazolam exposure; intravenous results differed.
  • The recorded outcome domains were Exposure and pharmacokinetics.
  • The result applies to the tested exposure: Quercetin 1,500 mg once and then daily for one week; oral midazolam 7.5 mg; Single dose and 1 week.

What this study can and cannot tell us

  • Very small study with route-dependent findings; the oral exposure ratio confidence interval crossed no effect. It does not support a universal CYP3A inhibition claim.
  • A change in blood exposure or a metabolic marker is not a demonstrated improvement in symptoms, disease events or lifespan. The tested formulation and co-administered medicines matter.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Phase 1 study of quercetin, a natural antioxidant for children and young adults with Fanconi anemia
Parinda A Mehta et al. · Blood advances · 2025
Tier 2
Randomised clinical trial to determine the safety of quercetin supplementation in patients with chronic obstructive pulmonary disease
Meilan K Han et al. · BMJ open respiratory research · 2020
Tier 2
Interaction study between antiplatelet agents, anticoagulants, diabetic therapy and a novel delivery form of quercetin
Antonella Riva et al. · Minerva cardioangiologica · 2019

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology